Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) has received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $256.00.
GOSS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a report on Tuesday, July 28th. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday.
Check Out Our Latest Analysis on GOSS
Gossamer Bio Trading Up 3.6%
Institutional Trading of Gossamer Bio
Several institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio during the second quarter worth approximately $2,467,000. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter worth $3,363,000. ARCH Venture Management LLC purchased a new stake in shares of Gossamer Bio during the second quarter worth about $1,326,004. BlackRock Inc. purchased a new stake in Gossamer Bio during the 2nd quarter worth approximately $1,262,000. Finally, Corient Private Wealth LP grew its holdings in shares of Gossamer Bio by 41.3% during the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after buying an additional 1,647,315 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.
Gossamer Bio Company Profile
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.
Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.
Featured Articles
- Five stocks we like better than Gossamer Bio
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
